Abstract:Aim: The aim of the study was to investigate whether miR-126, a regulator of MAPK signaling via targeting sprouty-related EVH1 domain-containing protein 1 (SPRED1) mRNA, is involved in the process by which icariside II (ICA II) ameliorates endothelial dysfunction in human cavernous endothelial cells (hCECs) exposed to a diabetic-like environment. Materials and methods: Primary hCECs were isolated and divided into three groups, normal control, diabetes mellitus (DM), and DM treated with ICA II. The cell proliferation and migration abilities of the hCECs were examined. The expression levels of endothelial-related microRNAs and relative target mRNAs (SPRED1, phosphoinositol-3 kinase regulatory subunit 2, and vascular cell adhesion molecule 1) of miR-126 were determined by real-time PCR. The protein expression of endothelial nitric oxide synthase, receptor for advanced glycation end products, and SPRED1, and MAPK signaling activities was determined by Western blot analysis. In addition, miR-126 agomir and antagomir were used for transfection into hCECs to further testify the association between miR-126 and its targeting mRNA SPRED1. Results: hCECs induced with glucose plus advanced glycation end product-BSA showed a significant decrease in endothelial nitric oxide synthase, Ki-67, and miR-126 expression; a downregulated cell migration ability and an increased receptor for advanced glycation end products level. ICA II could partially reverse these changes. SPRED1 mRNA showed a contrary tendency with the miR-126-3p changes. The level of SPRED1 protein increased after the hCECs were induced with glucose plus advanced glycation end product-BSA, and ICA II could rescue its aberrant expression. In addition, the MAPK pathway was downregulated in the hCECs under diabetic conditions, and ICA II could partially enhance its signaling activities. miR-126 was obviously downregulated, and SPRED1 was accordingly upregulated after miR-126 antagomir transfection, while ICA II treatment could recover the expressions of both miR-126 and SPRED1. Moreover, the upregulation of miR-126 and the inhibition of SPRED1 were noticed in the diabetic hCECs by further transfection with miR-126 agomir. Conclusion: ICA II could ameliorate endothelial dysfunction by regulating the MAPK pathway via miR-126/SPRED1 in hCECs exposed to a diabetic-like environment, and ICA II might be a protective agent for endothelial function in diabetic ED.

Icarisid II promotes proliferation and neuronal differentiation of neural stem cells via activating Wnt/β‐catenin signaling pathway

Icarisid II rescues cognitive dysfunction via activation of Wnt/β‐catenin signaling pathway promoting hippocampal neurogenesis in APP / PS1 transgenic mice

Icariin enhances neuronal survival after oxygen and glucose deprivation by increasing SIRT1.

Immunoregulation of Icariin Combined with Panax Notoginseng Saponins in Mice

Icariin Promotes Cell Proliferation and Regulates Gene Expression in Human Neural Stem Cells in Vitro

Icariside II Ameliorates Cognitive Impairments Induced by Chronic Cerebral Hypoperfusion by Inhibiting the Amyloidogenic Pathway: Involvement of BDNF/TrkB/CREB Signaling and Up-Regulation of PPARα and PPARγ in Rats

Effect of Astragaloside IV on Neural Stem Cell Transplantation in Alzheimer's Disease Rat Models

Effect of Neural Stem Cells Transplantation on Protein Expressions of Doublecortin and Nestin in Hippocampal Regions in App/ps1 Mice

Icariin promotes self-renewal of neural stem cells: An involvement of extracellular regulated kinase signaling pathway

Neural Stem Cell Transplants Improve Cognitive Function Without Altering Amyloid Pathology in an App/Ps1 Double Transgenic Model of Alzheimer'S Disease

Icariin Improves Cognitive Deficits and Activates Quiescent Neural Stem Cells in Aging Rats

Tanshinone Ii A, A Multiple Target Neuroprotectant, Promotes Caveolae-Dependent Neuronal

[Effects of Transplanted Neural Stem Cells on Synaptogenesis in APP/PS1 Mice].

Jujuboside a promotes proliferation and neuronal differentiation of APPswe-overexpressing neural stem cells by activating Wnt/β-catenin signaling pathway

Icariin ameliorates glycolytic dysfunction in Alzheimer's disease models by activating the Wnt/β‐catenin signaling pathway

Icariside II preconditioning evokes robust neuroprotection against ischaemic stroke, by targeting Nrf2 and the OXPHOS/NF-κB/ferroptosis pathway

Icariside II attenuates vascular remodeling via Wnt7b/CCND1 axis

Icariside II Protects Cardiomyocytes from Hypoxia‑induced Injury by Upregulating the Mir‑7‑5p/btg2 Axis and Activating the PI3K/Akt Signaling Pathway

Icariside II attenuates cardiac remodeling via AMPKα2/mTORC1 in vivo and in vitro.

Macrophage Migration Inhibitory Factor Promotes Proliferation and Neuronal Differentiation of Neural Stem/Precursor Cells Through Wnt/β-Catenin Signal Pathway

Icariside II ameliorates endothelial dysfunction by regulating the MAPK pathway via miR-126/SPRED1 in diabetic human cavernous endothelial cells.